ストックスクリーナーアプリを入手
1.56
0.64%
-0.01
前日終値:
$1.57
開ける：
$1.58
24時間の取引高:
9,533
Relative Volume:
0.15
時価総額：
$8.90M
収益：
-
当期純損益:
$-16.63M
株価収益率:
-3.6279
EPS:
-0.43
ネットキャッシュフロー:
$-21.84M
1週間 パフォーマンス:
-1.89%
1か月 パフォーマンス:
-13.33%
6か月 パフォーマンス:
-63.12%
1年 パフォーマンス:
-68.54%
1日の値動き範囲:
$1.55
$1.69
1週間の範囲:
$1.55
$1.6999
52週間の値動き範囲:
$1.05
$11.89
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
名前
Brainstorm Cell Therapeutics Inc
セクター
電話
201-488-0460
住所
1325 AVENUE OF AMERICAS, NEW YORK, NY
BCLI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
1.56 | 8.90M | 0 | -16.63M | -21.84M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-02-04 | アップグレード | Maxim Group | Hold → Buy |
| 2020-11-17 | ダウングレード | Maxim Group | Buy → Hold |
| 2016-12-19 | 繰り返されました | Maxim Group | Buy |
| 2015-12-22 | 繰り返されました | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc (BCLI) 最新ニュース
INVESTOR ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Brainstorm Cell Therapeutics Inc. to Host Earnings Call - ACCESS Newswire
Brainstorm Cell Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Expands By 21.3% - Defense World
Innovations in Stem Cell Therapy Market: Transforming - openPR
INVESTOR ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBCLI - ACCESS Newswire
5 Best Stem Cell Companies to Invest In (March 2025) - Securities.io
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com - Defense World
INVESTOR ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBCLI - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Brainstorm Cell Therapeutics Inc.(BCLI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Adaptive Biotechnologies (NASDAQ:ADPT) versus Brainstorm Cell Therapeutics (NASDAQ:BCLI) Financial Comparison - Defense World
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - Defense World
StockNews.com Initiates Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Amyotrophic Lateral Sclerosis (ALS) Market Future Prospects, - openPR
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded by StockNews.com to Hold Rating - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces Brainstorm Cell Therapeutics Inc. (BCLI) Investigation - ACCESS Newswire
Brainstorm Cell Therapeutics Appeals Nasdaq Delisting - MSN
Brainstorm Cell Therapeutics Appeals Nasdaq Delisting By Investing.com - Investing.com Australia
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded to “Hold” at StockNews.com - Defense World
Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail
Brainstorm Cell Therapeutics faces Nasdaq delisting By Investing.com - Investing.com Nigeria
Brainstorm Cell Therapeutics faces Nasdaq delisting - Investing.com
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting - GuruFocus.com
StockNews.com Downgrades Brainstorm Cell Therapeutics (NASDAQ:BCLI) to Sell - Defense World
Mesenchymal Stem Cells Market Outlook 2024: Emerging Trends and Regulatory Shifts Shaping the Future - WICZ
Global Stem Cell Characterization and Analysis Tool Market Size - WICZ
Equities Analysts Offer Predictions for BCLI FY2024 Earnings - Defense World
BCLI: Plans Coming Together for Phase 3b Trial of NurOwn in ALS - Smartkarma
BCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS… - MSN
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program - GuruFocus.com
BrainStorm Cell Therapeutics Announces Key Milestones and Strategic Plans for ALS Therapy NurOwn® - Tandav Media
BrainStorm Cell Advances NurOwn ALS Treatment with FDA Special Protocol Assessment and Manufacturing Deal - StockTitan
BrainStorm Issues 2024 Letter to Shareholders - PR Newswire
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update - The Eastern Progress Online
BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024 - The Eastern Progress Online
Amyotrophic Lateral Sclerosis (ALS) Market: Segmentation - openPR
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Kilgore News Herald
Autologous Cell Therapy Market Expected to Grow at Rapid Rates - openPR
BrainStorm secures patent for exosome technology By Investing.com - Investing.com Nigeria
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - Lelezard
Brainstorm Cell Therapeutics Inc (BCLI) 財務データ
収益
当期純利益
現金流量
EPS
Brainstorm Cell Therapeutics Inc (BCLI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lebovits Chaim | President & CEO |
Sep 30 '24 |
Buy |
0.23 |
22,000 |
5,016 |
1,186,865 |
| Dagher Ibrahim B. | Chief Medical Officer |
Jul 19 '24 |
Sale |
0.35 |
63,000 |
22,069 |
0 |
1.39%
0.55%
大文字化:
|
ボリューム (24 時間):